The Impact of Highly Active Antiretroviral Therapy on Non-AIDS-Defining Cancers among Adults with AIDS

Hessol, Nancy A.; Pipkin, Sharon; Schwarcz, Sandra; Cress, Rosemary D.; Bacchetti, Peter; Scheer, Susan

doi:10.1093/aje/kwm017

Cited by 184 publications

(149 citation statements)

References 20 publications

Supporting

Mentioning

130

Contrasting

Unclassified

Order By: Relevance

“…[1][2][3][4][5] Equally interesting is the fact that these malignancies in general presented at advanced stages which is a similar finding when compared with other studies. Delay in seeking care, even though possible, does not appear to be a significant problem in our study.…”

Section: Discussionsupporting

confidence: 86%

Non-AIDS–Defining Cancers in New Orleans

Ruiz¹,

Johnson

Reske³

et al. 2013

J Int Assoc Provid AIDS Care

View full text Add to dashboard Cite

Background: Non-AIDS-defining cancers in HIV-infected patients in the highly active antiretroviral therapy era have increased. To our knowledge a comprehensive review of non-AIDS-related malignancies in New Orleans has not yet been conducted. Methods: Databases from main institutions in New Orleans were queried retrospectively for the years 2001 to 2011. The International Classification of Diseases, Ninth Revision codes were used to search for HIV infection and cancer comorbidity. Results: A total of 16 patients were diagnosed with lung cancer (mean age 50 years) with 81% of the patients presenting with advanced stages. In all, 20 (mean age 47 years) were diagnosed with anal cancer, and 35% presented in late stages. In all, 14 patients (mean age 42 years) were diagnosed with Hodgkin Lymphoma, and 64% were diagnosed at late stage. A total of 5 women (mean age 44 years) were diagnosed with breast cancer with 40% of them presenting at late stage. Conclusion: Malignancies were diagnosed at late stages in the majority of the cases, presented with worse outcomes, and had higher recurrence rates. The role of HIV and other viruses (Epstein Barr virus, human papillomavirus) and the potential mechanisms or pathways of oncogene activation also need to be clarified.

show abstract

Section: Discussionsupporting

confidence: 86%

Non-AIDS–Defining Cancers in New Orleans

Ruiz¹,

Johnson

Reske³

et al. 2013

J Int Assoc Provid AIDS Care

View full text Add to dashboard Cite

show abstract

“…They reported 32 cases of PCa and found significantly increased standardized incidence ratios of PCa when compared to the general population (SIR ¼ 1.7). 7 However similar studies have noted disparate results.…”

Section: Prostate Cancermentioning

confidence: 97%

“…21,22 HIV Approximately 37 000 new cases of HIV were reported in the United States in 2006. 5 Hessol et al 7 identified more than 14 000 adults diagnosed with AIDS in San Francisco between 1990 and 2001 and identified 482 non-AIDSdefining cancers in the 60 months before or after the diagnosis of AIDS was made. They reported 32 cases of PCa and found significantly increased standardized incidence ratios of PCa when compared to the general population (SIR ¼ 1.7).…”

Section: Prostate Cancermentioning

confidence: 99%

See 1 more Smart Citation

HIV and prostate cancer: a systematic review of the literature

Silberstein

Downs

Lakin

et al. 2008

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Malignancy occurs with increased frequency in the HIV-positive population. The true incidence of prostate cancer in this population is unknown. In the few cases that have been presented in the literature, prostate cancer in HIV-positive men appears to behave much like it does in HIV-negative men. Prostate cancer is the most common malignancy in men and the second leading cause of cancer death. Approximately 800 000 men in the United States are HIV positive, and innovative therapies have dramatically improved survival. HIV disproportionately impacts ethnic groups with increased risk of prostate cancer and has been associated with increases in the incidence of certain malignancies. Despite the high prevalence of both diseases, there is relatively little literature about prostate cancer in HIV-positive patients. There is no consensus on how to screen or treat this patient population. We review the literature with regards to incidence, screening, treatment, and outcomes of this poorly characterized population. We briefly discuss the impact of highly active antiretroviral therapy and testosterone supplementation in the development of prostate cancer. A systematic review of the literature was conducted using MEDLINE key words 'HIV,' 'prostate,' 'prostate cancer' and 'AIDS.' Manual bibliographic review of cross-referenced items was also performed. A total of 176 unique abstracts and publications were reviewed; many authors provided data on the incidence of HIV and various malignancies including prostate cancer. Twelve unique publications providing detailed information on 60 patients with HIV and prostate cancer were identified. Prostate cancer is a common malignancy in HIV-positive men. With improved therapies for HIV and increasing survival, the importance for screening and treating prostate cancer is increasing. Acute outcomes of treatment do not demonstrate increased acute morbidity; however long-term outcomes have not been reported.

show abstract

“…The ultimate influence of the partial immune reconstitution and improved survival made possible by HAART on the risk of ICC and non-AIDS-defining cancers, notably HL, anal and liver cancer is, however, still unclear (Herida et al, 2003;Clifford et al, 2005;Dal Maso et al, 2005;Biggar et al, 2006;Engels et al, 2006;Hessol et al, 2007;Patel et al, 2008).…”

mentioning

confidence: 99%

Pattern of cancer risk in persons with AIDS in Italy in the HAART era

et al. 2009

View full text Add to dashboard Cite

A record-linkage study was carried out between the Italian AIDS Registry and 24 Italian cancer registries to compare cancer excess among persons with HIV/AIDS (PWHA) before and after the introduction of highly active antiretroviral therapy (HAART) in 1996. Standardised incidence ratios (SIR) were computed in 21951 AIDS cases aged 16 -69 years reported between 1986 and 2005. Of 101 669 person-years available, 45 026 were after 1996. SIR for Kaposi sarcoma (KS) and non-Hodgkin lymphoma greatly decreased in 1997 -2004 compared with 1986 -1996, but high SIRs for KS persisted in the increasingly large fraction of PWHA who had an interval of o1 year between first HIV-positive test and AIDS diagnosis. A significant excess of liver cancer (SIR ¼ 6.4) emerged in 1997 -2004, whereas the SIRs for cancer of the cervix (41.5), anus (44.0), lung (4.1), brain (3.2), skin (non-melanoma, 1.8), Hodgkin lymphoma (20.7), myeloma (3.9), and non-AIDS-defining cancers (2.2) were similarly elevated in the two periods. The excess of some potentially preventable cancers in PWHA suggests that HAART use must be accompanied by cancer-prevention strategies, notably antismoking and cervical cancer screening programmes. Improvements in the timely identification of HIV-positive individuals are also a priority in Italy to avoid the adverse consequences of delayed HAART use.

show abstract

The Impact of Highly Active Antiretroviral Therapy on Non-AIDS-Defining Cancers among Adults with AIDS

Cited by 184 publications

References 20 publications

Non-AIDS–Defining Cancers in New Orleans

Non-AIDS–Defining Cancers in New Orleans

HIV and prostate cancer: a systematic review of the literature

Pattern of cancer risk in persons with AIDS in Italy in the HAART era

Contact Info

Product

Resources

About